BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2012 related articles for article (PubMed ID: 28534943)

  • 1. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
    Pang L; Han S; Jiao Y; Jiang S; He X; Li P
    Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo.
    He XR; Han SY; Li XH; Zheng WX; Pang LN; Jiang ST; Li PP
    J Ethnopharmacol; 2017 May; 204():45-57. PubMed ID: 28412214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bu-Fei decoction and modified Bu-Fei decoction inhibit the growth of non-small cell lung cancer, possibly via inhibition of apurinic/apyrimidinic endonuclease 1.
    Jiang ST; Han SY; Pang LN; Jiao YN; He XR; Li PP
    Int J Mol Med; 2018 Apr; 41(4):2128-2138. PubMed ID: 29393411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 6. Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2.
    Li H; Huang N; Zhu W; Wu J; Yang X; Teng W; Tian J; Fang Z; Luo Y; Chen M; Li Y
    BMC Cancer; 2018 May; 18(1):579. PubMed ID: 29783929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
    Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
    J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
    Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA
    Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 13-Methyl-palmatrubine shows an anti-tumor role in non-small cell lung cancer via shifting M2 to M1 polarization of tumor macrophages.
    Wu Z; Zhou J; Chen F; Yu J; Li H; Li Q; Li W
    Int Immunopharmacol; 2022 Mar; 104():108468. PubMed ID: 35066343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma.
    Zhang Y; Du W; Chen Z; Xiang C
    Exp Cell Res; 2017 Oct; 359(2):449-457. PubMed ID: 28830685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
    Hong W; Xue M; Jiang J; Zhang Y; Gao X
    J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marsdenia tenacissima extract disturbs the interaction between tumor-associated macrophages and non-small cell lung cancer cells by targeting HDGF.
    Fu JL; Hao HF; Wang S; Jiao YN; Li PP; Han SY
    J Ethnopharmacol; 2022 Nov; 298():115607. PubMed ID: 35973634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression.
    Wang R; Zhang J; Chen S; Lu M; Luo X; Yao S; Liu S; Qin Y; Chen H
    Lung Cancer; 2011 Nov; 74(2):188-96. PubMed ID: 21601305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).
    Li Y; Liu H; Zhao Y; Yue D; Chen C; Li C; Zhang Z; Wang C
    Thorac Cancer; 2021 Oct; 12(20):2698-2709. PubMed ID: 34423566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of IFN-γ on the immunological microenvironment and TAM polarity in stage IA non-small cell lung cancer and its mechanisms.
    Zhao W; Wang H; Zhang X; Zhang L; Pu W; Ma Y; Chen W
    BMC Pulm Med; 2024 Jan; 24(1):46. PubMed ID: 38254043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Puerarin inhibits M2 polarization and metastasis of tumor-associated macrophages from NSCLC xenograft model via inactivating MEK/ERK 1/2 pathway.
    Kang H; Zhang J; Wang B; Liu M; Zhao J; Yang M; Li Y
    Int J Oncol; 2017 Feb; 50(2):545-554. PubMed ID: 28101568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
    Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
    Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 101.